4.46
-0.02 (-0.45%)
| Previous Close | 4.48 |
| Open | 4.47 |
| Volume | 1,797,756 |
| Avg. Volume (3M) | 1,502,908 |
| Market Cap | 215,704,784 |
| Price / Book | 0.910 |
| 52 Weeks Range | |
| Earnings Date | 8 Aug 2025 |
| Diluted EPS (TTM) | -4.62 |
| Total Debt/Equity (MRQ) | 10.78% |
| Current Ratio (MRQ) | 6.30 |
| Operating Cash Flow (TTM) | -147.29 M |
| Levered Free Cash Flow (TTM) | -68.80 M |
| Return on Assets (TTM) | -30.07% |
| Return on Equity (TTM) | -65.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | CARGO Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | -1.50 |
|
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 101.53% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |